Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Triple antithrombotic therapy (TAT) is recommended for atrial fibrillation (AF) patients post-acute coronary syndrome or percutaneous coronary intervention (PCI).
• Real-world adoption of TAT is limited due to increased bleeding risk and inconclusive trial data.
• Existing guidelines are based on registries, meta-analyses, and smaller trials.

Purpose of the Study:

• To evaluate the safety and efficacy of different antithrombotic strategies in AF patients undergoing PCI.
• To compare a dual-therapy regimen (rivaroxaban plus P2Y12 inhibitor) against traditional TAT.

Main Methods:

• The PIONEER AF-PCI trial enrolled 2124 patients with AF undergoing PCI.
• Patients were randomized to either TAT or a strategy involving a lower dose of rivaroxaban plus a single P2Y12 inhibitor, omitting aspirin.
• Primary safety endpoint was clinically significant bleeding; secondary endpoint was ischemic events.

Main Results:

• The rivaroxaban-based dual-therapy arm showed a significant reduction in clinically significant bleeding compared to TAT.
• No significant difference was observed in the secondary efficacy endpoint (ischemic events) between the two strategies.
• This suggests that omitting aspirin in dual therapy may offer equivalent ischemic protection without increasing thrombotic risk.

Conclusions:

• Dual therapy with low-dose rivaroxaban and a P2Y12 inhibitor is a safer alternative to TAT for AF patients undergoing PCI.
• Omitting aspirin in this patient population may be a viable strategy, balancing efficacy and safety.
• Further research is warranted to confirm these findings and refine treatment guidelines.